Author/Authors :
Khalili Pour, Elias Eye Research Center - Farabi Eye Hospital - Tehran University of Medical Sciences, Tehran, Iran , Bazvand, Fatemeh Eye Research Center - Farabi Eye Hospital - Tehran University of Medical Sciences, Tehran, Iran , Mehrabi Bahar, Mohammad Reza Eye Research Center - Farabi Eye Hospital - Tehran University of Medical Sciences, Tehran, Iran , Davood Abadi, Mahmood Eye Research Center - Farabi Eye Hospital - Tehran University of Medical Sciences, Tehran, Iran , Faghihi, Hooshang Eye Research Center - Farabi Eye Hospital - Tehran University of Medical Sciences, Tehran, Iran
Abstract :
Purpose: To report a case of chronic myelogenous leukemia (CML) treatment with imatinib mesylate in the remission phase who developed
unilateral macular choroidal neovascularization (CNV).
Methods: A 45‑year‑old male marketer with a 5‑year history of CML treated with imatinib mesylate presented with 2 months history of
progressive vision loss and metamorphopsia in the right eye.
Results: Fundus examination of the right eye revealed grey‑white elevated retinal lesion with indistinct borders in the macula and retinal
telangiectasia in the temporal macula. Fluorescein angiography (FA) and optical coherence tomography angiography (OCTA) confirmed
the presence of CNV in the right eye. After treatment with anti‑vascular endothelial growth factor (anti‑VEGF), macular CNV regressed
significantly.
Conclusion: Macular CNV must be kept in mind as a rare ophthalmic manifestation of patients with CML under treatment with imatinib
even in the remission phase.
Keywords :
Bevacizumab , Choroidal neovascularization , Chronic myelogenous leukemia , Imatinib mesylate , Pachychoroid neovasculopathy
